A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis María Uribarri, PhD, Itsaso Hormaeche, PhD, Rafael Zalacain, MD,

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Phenotypic Heterogeneity of Potentially Curable Non–Small-Cell Lung Cancer: Cohort Study with Cluster Analysis Lama Sakr, MD, MSc, FRCPC, David Small,

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

ALK FISH and IHC: You Cannot Have One without the Other

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer Xiaoxia Chen,

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Stephen A. Deppen, PhD, Jeffrey D. Blume, PhD, Melinda C

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Establishment of a Multi-Analyte Serum Biomarker Panel to Identify Lymph Node Metastases in Non-small Cell Lung Cancer Jeffrey A. Borgia, PhD, Sanjib.

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Frank Detterbeck, MD Journal of Thoracic Oncology

Comparison of the Yield of Different Diagnostic Procedures for Cellular Differentiation and Genetic Profiling of Non–Small-Cell Lung Cancer Amr S. Albanna,

Anil Vachani, MD, Harvey I. Pass, MD, William N. Rom, MD, David E

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Anya M. Litvak, MD, Paul K. Paik, MD, Kaitlin M. Woo, MS, Camelia S

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Detection of Lung Cancer by Automated Sputum Cytometry

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

A Prognostic Model to Predict Mortality among Non–Small-Cell Lung Cancer Patients in the U.S. Military Health System Jie Lin, PhD, MPH, Corey A. Carter,

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

Erratum Journal of Thoracic Oncology

Early Stage Lung Cancer: Progress in the Last 40 Years

Adam Falconi, BSc, Pharm, Gilberto Lopes, MD, MBA, Jayson L

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non–Small-Cell Lung Cancers

Mitotic Inhibitors Journal of Thoracic Oncology

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,

Mirror Mirror on the Wall, Who Is the Fairest of Them All

SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma Christoph Kneip, PhD, Bernd Schmidt, MD, Anke Seegebarth, Sabine Weickmann,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin.

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Joan J. Ryoo, MD, MSHS, Jennifer L. Malin, MD, PhD, Diana L

Phenotypic Heterogeneity of Potentially Curable Non–Small-Cell Lung Cancer: Cohort Study with Cluster Analysis Lama Sakr, MD, MSc, FRCPC, David Small,

Lung Cancer in New Zealand: Patterns of Secondary Care and Implications for Survival Wendy Stevens, MBBS, Graham Stevens, MD, FRANZCR, John Kolbe, MBBS,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Mark I. Block, MD The Annals of Thoracic Surgery

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis María Uribarri, PhD, Itsaso Hormaeche, PhD, Rafael Zalacain, MD, Guillermo Lopez-Vivanco, MD, PhD, Antonio Martinez, PhD, Daniel Nagore, PhD, M. Begoña Ruiz-Argüello, PhD Journal of Thoracic Oncology Volume 9, Issue 10, Pages 1504-1512 (October 2014) DOI: 10.1097/JTO.0000000000000282 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Representative silver-stained proteome of a bronchoalveolar lavage sample. The 51 selected spots are circled in red. The main information of each spot is listed in Table 2. Journal of Thoracic Oncology 2014 9, 1504-1512DOI: (10.1097/JTO.0000000000000282) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Influence of cancer stage. Box plots represent the amount of protein (logarithm values of MFIs) in the vertical axis and the different cancer stages in the abscissa. In gray, values of the control samples (0, n = 48) are shown, whereas in black the values of the samples from patients with lung cancer distributed by disease stage (I + II, n = 18; IIIA, n = 24; IIIB, n = 36; and IV, n = 109) are represented. *Analysis of variance p value of 0.05 or less when comparing controls with cancer patients at different stages. MFIs, median fluorescence intensities. Journal of Thoracic Oncology 2014 9, 1504-1512DOI: (10.1097/JTO.0000000000000282) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Performance of a biomarker panel for lung cancer diagnosis (box plot of the logistic regression values, corresponding receiver operating characteristic curves and contingency tables). A, Control versus Cancer comparison; (B) SCLC versus NSCLC comparison. SCLC, small-cell lung cancer; NSCLC, non–small-cell lung cancer; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the curve. Journal of Thoracic Oncology 2014 9, 1504-1512DOI: (10.1097/JTO.0000000000000282) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions